Findings from a Phase III study highlight the demonstrated action of donanemab-azbt (brand name Kisunla) in slowing the ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Explore the growth potential of the Alzheimer's disease-modifying therapies (DMTs) market as lecanemab gains FDA approval in 2023. With several late-stage trials underway, anticipate market shifts ...

Shares of Vertex Pharmaceuticals plunged more than 14% to $404.89 after it release disappointing top-line results from its recently completed Phase II, randomized, double-blind, placebo-controlled ...